Direkt zum Inhalt
Merck

Impact of IgG1 N-glycosylation on their interaction with Fc gamma receptors.

Current research in immunology (2020-06-27)
Florian Cambay, Céline Raymond, Denis Brochu, Michel Gilbert, The Minh Tu, Christiane Cantin, Anne Lenferink, Maxime Grail, Olivier Henry, Gregory De Crescenzo, Yves Durocher
ZUSAMMENFASSUNG

The effector functions of the IgGs are modulated by the N-glycosylation of their Fc region. Particularly, the absence of core fucosylation is known to increase the affinity of IgG1s for the Fcγ receptor IIIa expressed by immune cells, in turn translating in an improvement in the antibody-dependent cellular cytotoxicity. However, the impact of galactosylation and sialylation is still debated in the literature. In this study, we have investigated the influence of high and low levels of core fucosylation, terminal galactosylation and terminal α2,6-sialylation of the Fc N-glycans of trastuzumab on its affinity for the FcγRIIIa. A large panel of antibody glycoforms (i.e., highly α2,6-sialylated or galactosylated IgG1s, with high or low levels of core fucosylation) were generated and characterized, while their interactions with the FcγRs were analysed by a robust surface plasmon resonance-based assay as well as in a cell-based reporter bioassay. Overall, IgG1 glycoforms with reduced fucosylation display a stronger affinity for the FcγRIIIa. In addition, fucosylation, and the presence of terminal galactose and sialic acids are shown to increase the affinity for the FcγRIIIa as compared to the agalactosylated forms. These observations perfectly translate in the response observed in our reporter bioassay.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
GlycoProfile 2-AB Labeling Kit